Microburst Vagus Nerve Stimulator (VNS) Therapy Feasibility Study

• Sponsor: LivaNova (Industry)
• Overall Status: Completed
• CT.gov ID: NCT03446664
• Collaborator: (none)
• Enrollment: 33
• Locations: 9
• Arm: 1
• Actual Duration (Months): 53.4
• Patients Per Site: 3.7
• Patients Per Site Per Month: 0.1

Study Details

Study Description

Brief Summary

Evaluate the initial safety and effectiveness of Microburst VNS stimulation in subjects with refractory epilepsy.

Condition or Disease	Intervention/Treatment	Phase
Epilepsies, Partial; Epilepsy, Tonic-Clonic	Device: Microburst Stimulation	Phase 1

Study Design

• Study Type: Interventional
• Actual Enrollment: 33 participants
• Allocation: N/A
• Intervention Model: Single Group Assignment
• Intervention Model Description: Two cohorts of subjects with refractory epilepsy; (1) subjects with primary generalized tonic-clonic seizures and (2) subjects with partial onset seizures including complex partial seizures with or without secondary generalization.Two cohorts of subjects with refractory epilepsy; (1) subjects with primary generalized tonic-clonic seizures and (2) subjects with partial onset seizures including complex partial seizures with or without secondary generalization.
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: Microburst VNS Therapy Feasibility Study in Subjects With Refractory Epilepsy
• Actual Study Start Date: Feb 27, 2018
• Actual Primary Completion Date: Jul 30, 2021
• Actual Study Completion Date: Aug 10, 2022

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Microburst Stimulation Microburst stimulation to tolerability and effectiveness	Device: Microburst Stimulation; Implantable generator with new stimulation feature under study to determine the safety and effectiveness of device stimulation on different seizure types.

Outcome Measures

Primary Outcome Measures

1. Efficacy Primary Endpoint: Percent change from baseline in seizure frequency [Up to 12 months study visit]

   For the primary endpoint, the change in the seizure frequency per month compared to baseline will be evaluated for each subject at follow-up visits month 6 and 12.

2. Safety Primary Endpoint: Occurrence of stimulation related Adverse Events [Up to 12 months study visit]

   Assess stimulation/device related adverse events at follow-up visits month 6 and 12.

Secondary Outcome Measures

1. Change from baseline in seizure frequency per month based on seizure diary provided by the sponsor [Up to 12 months study visit]

2. Change from baseline in seizure severity [Up to 12 months study visit]

   As measured by the Seizure Severity Questionnaire (SSQ) scale (Cramer, 2002).

3. Change from baseline in quality of life [Up to 12 months study visit]

   As measured by the QOLIE-31-P for adults 18 years and older (Cramer et al.; 1998) and QOLIE-AD-48 for adolescents 12 to 17 years (Cramer et al.; 1999).

4. Change from baseline in antiepileptic drug (AED) load [Up to 12 months study visit]

   Estimated as the sum of the prescribed daily dose (PDD)/defined daily dose (DDD) ratios for each AED included in the treatment regimen (Deckers et al., 1997), where DDD (WHO ATC/DDD index) corresponds to the assumed average therapeutic daily dose of a drug used for its main indication.

5. Suicidality as measured by the Columbia Suicide Severity Rating Scale (C-SSRS) [Up to 12 months study visit]

6. All adverse events [Up to 12 months visit]

Eligibility Criteria

Criteria

• Ages Eligible for Study: 12 Years and Older
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Inclusion Criteria:

1. Clinical diagnosis of medically refractory epilepsy with primary generalized tonic-clonic seizures (limited to 20 subjects) or partial onset seizures including complex partial seizures with or without secondary generalization (limited to 20 subjects).

2. Must be on adjunctive antiepileptic medications.

3. Willing and capable to undergo multiple evaluations with functional magnetic resonance imaging (fMRI), electroencephalogram (EEG) and electrocardiogram (ECG).

4(A) For subjects with partial onset seizures: An average of ≥ 3 countable seizures per month based on seizure diary during the 3 month baseline period and no seizure-free interval greater than 30 days during those 3 months.

4(B) For subjects with PGTCs: Have at least ≥ 3 countable seizures during the 3 month baseline period. Note: Each seizure within a cluster may be counted as separate seizures.

1. 12 years of age or older.

2. Subject is a male or non-pregnant female adequately protected from conception. Females of childbearing potential must use an acceptable method of birth control.

3. Provide written informed consent-assent/Health Insurance Portability and Accountability Act (HIPAA) authorization and self-reported measures with minimal assistance as determined by the investigator.

Exclusion Criteria:

1. Currently using, or are expected to use, short-wave diathermy, microwave diathermy, or therapeutic ultrasound diathermy.

2. A VNS Therapy System implant would (in the investigator's judgment) pose an unacceptable surgical or medical risk for the subject.

3. A planned procedure that is contraindicated for VNS therapy.

4. History of implantation of the VNS Therapy System.

5. Currently receiving treatment from an active implantable medical device.

6. Presence of contraindications to MRI per the MRI subject screening record.

7. Known clinically meaningful cardiovascular arrhythmias currently being managed by devices or treatments that interfere with normal intrinsic heart rate responses (e.g., pacemaker dependency, implantable defibrillator, beta adrenergic blocker medications).

8. History of chronotropic incompetence (commonly seen in subjects with sustained bradycardia [heart rate < 50 bpm]).

9. Cognitive or psychiatric deficit that in the investigator's judgment would interfere with the subject's ability to accurately complete study assessments.

10. History of status epilepticus within 1 year of study enrollment.

11. Dependent on alcohol or narcotic drugs as defined by DSM IV-TR within the past 2 years, based on history. Tests for drug or alcohol use will not be administered.

12. Currently being treated with prescribed medication that contains cannabis or cannabis related substance including recreational use.

13. Any history of psychogenic non-epileptic seizures.

14. Currently participating in another clinical study without LivaNova written approval.

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	University of Alabama at Birmingham	Birmingham	Alabama	United States	35294
2	University of Denver Colorado	Denver	Colorado	United States	80204
3	Mayo Clinic Florida	Jacksonville	Florida	United States	32224
4	Rush University	Chicago	Illinois	United States	60612
5	Northwestern University	Evanston	Illinois	United States	60208
6	Weil-Cornell Medical College	Ithaca	New York	United States	10065
7	Duke University	Durham	North Carolina	United States	27708
8	University of Utah	Salt Lake City	Utah	United States	84112
9	Ghent University Hosptial	Ghent		Belgium

Sponsors and Collaborators

• LivaNova

Investigators

• Principal Investigator: Selim Benbadis, MD, University of South Florida Health

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

• Responsible Party: LivaNova
• ClinicalTrials.gov Identifier: NCT03446664
• Other Study ID Numbers: LNN001
• First Posted: Feb 27, 2018
• Last Update Posted: Aug 24, 2022
• Last Verified: Aug 1, 2022

• Individual Participant Data (IPD) Sharing Statement: No
• Plan to Share IPD: No
• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: Yes
• Additional relevant MeSH terms: Epilepsy; Epilepsies, Partial; Epilepsy, Tonic-Clonic; Epilepsy, Generalized

Study Results

No Results Posted as of Aug 24, 2022